Renovaro to Acquire Predictive Oncology: A Merger of AI-Driven Cancer Research Powerhouses

Merger Announcement and Strategic Vision

Renovaro Inc. (NASDAQ: RENB) and Predictive Oncology Inc. (NASDAQ: POAI) have announced a binding agreement for Renovaro to acquire Predictive Oncology in an all-stock transaction 1

1

2

2

3

3

. This merger aims to create a powerhouse in AI-driven cancer research, combining Predictive Oncology's extensive biobank and AI-driven drug discovery platform with Renovaro's multi-disciplinary artificial intelligence expertise.

Key Terms of the Acquisition

The acquisition will be executed through a 1:1 exchange of Predictive Oncology's common stock for newly created preferred stock of Renovaro 1

1

. This preferred stock is automatically redeemable for $3 per share after 18 months and can be converted to Renovaro common stock under specific conditions 3

3

. The merger is subject to Renovaro raising a minimum of $15 million and approval from Predictive Oncology's shareholders 1

1

.

Synergies and Strategic Benefits

The merger is expected to create significant scientific and operational synergies:

1. Complementary AI/ML Platforms: The combined entity will leverage both companies' proprietary AI platforms to accelerate drug discovery and reduce development risks 1

   1

   .

2. Extensive Biobank Access: Renovaro gains access to Predictive Oncology's vast biobank of over 150,000 patient tumor samples and 200,000 pathology slides 2

   2

   .

3. Cost Savings: The merger is anticipated to reduce operating expenses by more than 30% on a combined basis 1

   1

   .

4. Enhanced Diagnostic Capabilities: The integration aims to improve cancer diagnostics, personalized treatment protocols, and recurrence monitoring 2

   2

   .

AI-Driven Advancements in Oncology

The combined company will focus on several key areas:

1. Early Cancer Detection: Renovaro's AI platform will be enhanced with Predictive Oncology's data to improve early cancer detection and recurrence monitoring 2

   2

   .

2. Personalized Treatment: The merger aims to assist physicians in individualizing cancer therapy to improve treatment outcomes 2

   2

   .

3. Drug Discovery: The integration of AI platforms is expected to accelerate biomarker discovery and drug development across multiple cancer types 2

   2

   .

Leadership and Future Plans

David Weinstein, CEO of Renovaro, and Raymond Vennare, CEO of Predictive Oncology, expressed enthusiasm about the merger's potential to revolutionize cancer patient care 1

1

2

2

. The companies plan to finalize their leadership team and Board of Directors in the coming weeks, along with detailing the combined company's R&D priorities 3

3

.

Market Impact and Industry Position

This merger positions the combined entity as a significant player in the AI-driven oncology field. By integrating Predictive Oncology's proven AI/ML platform, which boasts a 92% accuracy in predicting tumor-drug responses, with Renovaro's liquid biopsy approach, the company aims to launch a decision support platform for medical oncologists in 2025 2

2

.

Conclusion

The Renovaro-Predictive Oncology merger represents a significant development in the application of AI to cancer research and treatment. By combining their strengths in AI, biobanking, and multi-omic data analysis, the new entity aims to offer comprehensive solutions from early diagnosis to personalized therapies, potentially transforming the landscape of cancer care and drug discovery.